Forge a Successful CRISPR Therapeutic Path With High-Quality GMP sgRNA

The rapid increase in CRISPR-mediated cell and gene therapies in clinical trials over the past few years is a testimony to the promising future of next-generation medicine.

While improved technological prowess empowers the development of more CRISPR-edited therapies, supply-chain and manufacturing hurdles still pose significant barriers to clinical and commercialization timelines.

Watch this webinar to learn more about:

• The state of CRISPR cell and gene therapies
• Challenges in CRISPR therapy manufacturing
• A next-generation manufacturing facility